

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>NOHRA GUY P</u> (Last) (First) (Middle) <u>ONE EMBARCADERO CENTER</u> <u>SUITE 4050</u> (Street) <u>SAN FRANCISCO CA 94111</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>FLAMEL TECHNOLOGIES SA [FLML]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) See Footnotes
	3. Date of Earliest Transaction (Month/Day/Year) <u>10/02/2003</u>	
6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/02/2003		D		1,181,017	D	\$33.25	170,937	I	See Footnote 1 ⁽¹⁾
Common Stock	10/02/2003		D		674,468	D	\$33.25	97,620	I	See Footnote 2 ⁽²⁾
Common Stock	10/02/2003		D		44,515	D	\$33.25	6,443	I	See Footnote 3 ⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

Explanation of Responses:

- Alta BioPharma L.P. ("Alta BioP") converted its common stock into ADS pursuant to Flamel Technologies Form F-3 Reg#333-108-202. Alta Partners directly or indirectly provides investment advisory services to various venture capital funds, including Alta BioP. The General Partner of Alta BioP exercises sole voting and investment power with respect to the shares held by the fund. The principals of Alta Partners are Jean Deleage, Guy Nohra, Garrett Gruener, Daniel Janney, Alix Marduel (collectively known as the "principals"). Certain principals of Alta Partners are managing directors of Alta BioPharma Mgt, LLC (the GP of Alta BioP), as managing directors they may be deemed to share voting and investment powers of the shares held by the funds. These principals disclaim beneficial ownership, except to the extent of their proportionate interests therein. X\ref to Form 4 filed for Alta Partners on 10/3/03.
- Flamel Chase Partners (AltaBio),LLC ("Flamel Chase") converted its common stock into ADS pursuant to Flamel Technologies Form F-3 Reg#333-108-202. Alta Partners directly or indirectly provides investment advisory services to various venture capital funds, including Flamel Chase. The managing member of Flamel Chase exercises sole voting and investment power with respect to the shares held by the fund. The principals of Alta Partners are Jean Deleage, Guy Nohra, Garrett Gruener, Daniel Janney, Alix Marduel (collectively known as the "principals"). Certain principals of Alta Partners are members of Alta/Chase BioPharma Management, LLC (the managing member of Flamel Chase), as members they may be deemed to share voting and investment powers of the shares held by the funds. These principals disclaim beneficial ownership of all such shares, except to the extent of their proportionate interests therein. X\ref to Form 4 for Alta Partners filed on 10/3/03.
- Alta Embarcadero BioPharma Partners,LLC ("Alta Embarcadero") converted its common stock into ADS pursuant to Flamel Technologies Form F-3 Reg#333-108-202. Alta Partners directly or indirectly provides investment advisory services to various venture capital funds, including Alta Embarcadero. The members of Alta Embarcadero exercises sole voting and investment power with respect to the shares held by the fund. The principals of Alta Partners are Jean Deleage, Guy Nohra, Garrett Gruener, Daniel Janney, Alix Marduel (collectively known as the "principals"). Certain principals of Alta Partners are members of Alta Embarcadero, as members they may be deemed to share voting and investment powers of the shares held by the funds. These principals disclaim beneficial ownership of all such shares, except to the extent of their proportionate interests therein. X\ref to Form 4 for Alta Partners filed on 10/3/03.

Remarks:

This form 4 is part 2 of a group filing. Part one is filed under the reporting name of Alta Partners, the entity that is the beneficial owners of the shares. It was filed on 10/3/03.

Guy Nohra 10/03/2003
 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.